← Leaderboards
Zhi Q. Yao
East Tennessee State University
$6,116,789
Attributed
$6,116,789
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $682.5K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,116,789 · 8
VA$0 · 5
By mechanism
R01$3,873,997 · 3
R21$1,225,674 · 3
R15$1,017,118 · 2
I01$0 · 2
IS1$0 · 3
Top collaborators
No co-investigators on record.
Most similar at East Tennessee State University
Same institution · by research overlap
- Juan Zhao$704,290
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingVirus DiseasesCellsTranslational StudyViralImmuneImmune ResponseResponseExhibitsT-LymphocyteFunctional DisorderChronicHepatitis B VirusImpairmentHepatitis C VirusVirusCd4 Positive T LymphocytesInfectionMorbidity - Disease RateExhaustionT Cell ResponseHiv InfectionsAgingMortality
Grant awards (36)
Engineered exosomes carrying synthetic gRNA/Cas9 targeting HBV-infected cells$344,043
R01 · FY2025 · AI · contact PI
Engineering exosomes for new gRNA/Cas therapeutics to eliminate HBV infection$173,829
R21 · FY2025 · AI · contact PI
A novel CRISPR/Cas12 system targeting HBV DNA for gene therapy$19,201
R01 · FY2025 · AI · contact PI
Telomere attrition and T cell aging in vaccine failure during HIV infection$0
I01 · FY2025 · VA · contact PI
Engineered exosomes carrying synthetic gRNA/Cas9 targeting HBV-infected cells$362,222
R01 · FY2024 · AI · contact PI
Engineering exosomes for new gRNA/Cas therapeutics to eliminate HBV infection$225,000
R21 · FY2024 · AI · contact PI
Telomere attrition and T cell aging in vaccine failure during HIV infection$0
I01 · FY2024 · VA · contact PI
Mitochondrial Dysfunction in Aging CD4 T cells in HIV-immune Non-responders.$375,000
R15 · FY2023 · AG · contact PI
Telomere attrition and T cell aging in vaccine failure during HIV infection$0
I01 · FY2023 · VA · contact PI
Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection$185,621
R21 · FY2022 · AI · contact PI
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual$0
I01 · FY2022 · VA · contact PI
HIV infection-induced mitochondrial dysfunction and premature T cell aging$427,618
R15 · FY2021 · AG · contact PI
Dual specific gene editing drugs delivered by nanoparticles targeting HBV/HIV coinfection$234,224
R21 · FY2021 · AI · contact PI
Droplet Digital PCR System$0
IS1 · FY2021 · VA · contact PI
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual$0
I01 · FY2021 · VA · contact PI
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual$0
I01 · FY2020 · VA · contact PI
miRNA-mediated premature T cell aging in vaccine failure during viral infection$365,000
R01 · FY2019 · AI · contact PI
Telomere loss and T cell aging in HBV vaccine response in HIV-infected individual$185,000
R21 · FY2019 · AI · contact PI
Gender difference in miRNA-mediated T cell aging during viral infection$96,200
R01 · FY2019 · AI · contact PI
Multiuser Advanced Confocal Microscope$0
IS1 · FY2019 · VA · contact PI
Telomere loss and T cell aging in HBV vaccine response in HCV-infected individual$0
I01 · FY2019 · VA · contact PI
Premature T cell aging and vaccine failure in chronic viral infection$0
I01 · FY2019 · VA · contact PI
miRNA-mediated premature T cell aging in vaccine failure during viral infection$365,000
R01 · FY2018 · AI · contact PI
Telomere loss and T cell aging in HBV vaccine response in HIV-infected individual$222,000
R21 · FY2018 · AI · contact PI
Premature T cell aging and vaccine failure in chronic viral infection$0
I01 · FY2018 · VA · contact PI
miRNA-mediated premature T cell aging in vaccine failure during viral infection$365,000
R01 · FY2017 · AI · contact PI
Premature T cell aging and vaccine failure in chronic viral infection$0
I01 · FY2017 · VA · contact PI
miRNA-mediated premature T cell aging in vaccine failure during viral infection$365,000
R01 · FY2016 · AI · contact PI
ShEEP Proposal for a Multiuser Advanced Biosafe Flow Cytometer$0
IS1 · FY2016 · VA · contact PI
Premature T cell aging and vaccine failure in chronic viral infection$0
I01 · FY2016 · VA · contact PI
miRNA-mediated premature T cell aging in vaccine failure during viral infection$365,000
R01 · FY2015 · AI · contact PI
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection$317,550
R01 · FY2015 · DK · contact PI
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection$285,795
R01 · FY2014 · DK · contact PI
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection$306,436
R01 · FY2013 · DK · contact PI
Tim-3-mediated IL-12 dysregulation in antiviral responses to HCV infection$317,550
R01 · FY2012 · DK · contact PI
The role of PD-1 and SOCS-1 in HCV core/gC1qR-mediated IL-12 suppression$214,500
R15 · FY2009 · AI · contact PI